Brief: Oncotelic Initiates Phase 2 Trial Evaluating Ot-101 In Combination With Keytruda® For Mesothelioma
01/12/2021 14:49
Dec 1 (Reuters) - Oncotelic Therapeutics Inc OTLC.PK :
* ONCOTELIC INITIATES PHASE 2 TRIAL EVALUATING OT-101 IN
COMBINATION WITH KEYTRUDA® FOR MESOTHELIOMA
Source text for Eikon: ID:nGNX9HMjWm
Further company coverage: OTLC.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas